We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+40.65%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$3.13B
AUM Growth
+$681M
Cap. Flow
-$365M
Cap. Flow %
-11.64%
Top 10 Hldgs %
43.55%
Holding
107
New
15
Increased
23
Reduced
25
Closed
31

Top Buys

Rank Stock Value
1
AHCO icon
AdaptHealth
AHCO
+$171M
2
TNDM icon
Tandem Diabetes Care
TNDM
+$55.9M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$37.8M
4
KRRO icon
Korro Bio
KRRO
+$22.1M
5
ARDX icon
Ardelyx
ARDX
+$21.9M

Top Sells

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$57.9M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$52.7M
3
CHRS icon
Coherus Oncology
CHRS
+$31.2M
4
IMMU
Immunomedics Inc
IMMU
+$26.3M
5
DFBHU
DFB Healthcare Acquisitions Corp. Unit
DFBHU
+$25.8M

Sector Composition

Rank Sector Weight
1 Healthcare 77.62%
2 Financials 0.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KOD icon
51
Kodiak Sciences
KOD
$2.67B
$14.4M 0.46%
+200,000
New +$7.28M
MNK
52
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$14.1M 0.45%
4,026,750
-164,577
-4% -$514K
KIDS icon
53
OrthoPediatrics
KIDS
$494M
$10.6M 0.34%
+225,000
New +$8.72M
ATRC icon
54
AtriCure
ATRC
$1.77B
$9.52M 0.3%
292,777
– –
SYRS
55
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$8.77M 0.28%
126,895
– –
ISEE
56
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$8.58M 0.27%
+1,000,000
New +$3.57M
TXMD icon
57
TherapeuticsMD
TXMD
$23.8M
$5.45M 0.17%
+45,000
New +$6.47M
STIM icon
58
Neuronetics
STIM
$113M
$4.83M 0.15%
1,075,000
+735,488
+217% +$4.57M
XFOR icon
59
X4 Pharmaceuticals
XFOR
$360M
$4.81M 0.15%
14,981
-3,810
-20% -$1.37M
ITMR
60
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
$4.04M 0.13%
314,136
– –
PBYI icon
61
Puma Biotechnology
PBYI
$434M
$3.47M 0.11%
+396,472
New +$3.28M
SWAV
62
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$3.07M 0.1%
+70,000
New +$2.59M
INGN icon
63
Inogen
INGN
$178M
$2.53M 0.08%
37,016
-154,644
-81% -$9.7M
AERI
64
PUT
DELISTED
Aerie Pharmaceuticals
AERI
$2.51M 0.08%
+103,800
New +$2.15M
ADVM
65
DELISTED
Adverum Biotechnologies
ADVM
$2.44M 0.08%
+21,134
New +$1.86M
ALPN
66
DELISTED
Alpine Immune Sciences Inc
ALPN
$956K 0.03%
248,992
-157,934
-39% -$492K
TARA icon
67
Protara Therapeutics
TARA
$230M
$832K 0.03%
50,725
+20,103
+66% +$231K
NEOS
68
DELISTED
Neos Therapeutics, Inc
NEOS
$485K 0.02%
320,993
– –
ZVRA icon
69
Zevra Therapeutics
ZVRA
$755M
$196K 0.01%
32,356
-10,901
-25% -$86.6K
ANAB icon
70
AnaptysBio
ANAB
$1.72B
– –
-425,443
Closed -$14.9M
ATEC icon
71
Alphatec Holdings
ATEC
$1.31B
– –
-536,517
Closed -$2.69M
AVDL
72
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-2,722,241
Closed -$11.3M
AXGN icon
73
Axogen
AXGN
$2.12B
– –
-1,842,330
Closed -$23M
BBIO icon
74
BridgeBio Pharma
BBIO
$15.9B
– –
-290,000
Closed -$6.23M
CHRS icon
75
Coherus Oncology
CHRS
$216M
– –
-1,540,305
Closed -$31.2M
1 2
3
4

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q4 2019 Portfolio in Review

As of Q4 2019, Deerfield Management held 107 positions worth $3.13B, up 28% from $2.45B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Deerfield Management withdrew a net $365M in Q4 2019, closing 31 positions and reducing 25 holdings. Its most notable exit was Coherus Oncology, an estimated $31.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 71% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in AdaptHealth worth $189M.

  • Deerfield Management's largest Q4 2019 buy was AdaptHealth: 17,199,888 shares worth $189M.
  • Deerfield Management added most to Tandem Diabetes Care in Q4 2019, an estimated $55.9M increase.
  • Deerfield Management's biggest Q4 2019 reduction was Aerie Pharmaceuticals, cutting an estimated $57.9M.
  • Deerfield Management fully exited Coherus Oncology in Q4 2019, selling an estimated $31.2M.
  • Deerfield Management's ten largest holdings make up 44% of its $3.13B portfolio in Q4 2019.
  • Deerfield Management opened 15 new positions and closed 31 in Q4 2019.
  • Deerfield Management's portfolio value rose 28% quarter-over-quarter to $3.13B.

Based on Deerfield Management's 13F filing for Q4 2019, filed 14 Feb 2020.